ELIGIBILITY criteria for the COVID-19 oral antiviral treatment nirmatrelvir and ritonavir (Paxlovid) will be further expanded on the PBS to include individuals aged 5059 years with one known risk factor.
The change will ensure greater access to Paxlovid for people who are at risk of severe disease.
The PBS eligibly criteria for molnupiravir (Lagevrio) remains unchanged.
Avatrombopag (Doptelet) is also now listed on the PBS for the first time to treat severe thrombocytopenia in patients with chronic idiopathic thrombocytopenia purpura.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jul 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jul 23
Warning: Undefined variable $o_shortcode_atts in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1263
Warning: Undefined variable $output in /home/pharmacydaily.com.au/public_html/wp-content/themes/child-custom-theme/functions.php on line 1266
